Structure elucidation of a specific fluorophore from the aging extracellular matrix revealed the presence of a protein crosslink formed through nonenzymatic glycosylation of lysine and arginine residues. The unexpected finding that a pentose instead of a hexose is involved in the crosslinking process suggested that the crosslink, named pentosidine, might provide insight into abnormalities of pentose metabolism in aging and disease. This hypothesis was investigated by quantitating pentosidine in hydrolysates of 103 human skin specimens obtained randomly at autopsy. Pentosidine level was found to increase exponentially from 5 to 75 pmol/mg collagen over lifespan (r = 0.86, P less than 0.001). A three-to tenfold increase was noted in insulin-dependent diabetic and nondiabetic subjects with severe end-stage renal disease requiring hemodialysis (P less than 0.001). Moderately elevated levels were also noted in some very old subjects, some subjects with non-insulin dependent diabetes, and two subjects with cystic fibrosis and diabetes. The cause of the abnormal pentose metabolism in these conditions is unknown but may relate to hemolysis, impaired pentose excretion, cellular stress, and accelerated breakdown of ribonucleotides. Thus, pentosidine emerges as a useful tool for assessment of previously unrecognized disorders of pentose metabolism in aging and disease. Its presence in red blood cells and plasma proteins suggests that it might be used as a measure of integrated pentosemia in analogy […] Research Article
Introduction
Recently this laboratory reported the presence of skin collagen-linked fluorescence that accumulates during normal aging and that was increased in 98% of insulin-dependent diabetic subjects (1) . There was an overall correlation between collagen-linked fluorescence and severity of retinopathy, arterial and joint stiffness, and systolic blood pressure. The analogy between the fluorescence properties of diabetic skin and those of collagen incubated with glucose suggested that advanced glycosylation (Maillard) reaction had formed at a higher rate in diabetes, presumably reflecting chronic elevation of glycemia over many years.
Work was initiated to substantiate the glucose-derived nature of the fluorescence. Human insoluble collagen was fractionated into low molecular weight peptides and two distinct fluorescent molecules were obtained (2) . The fluorophore that was increased in 98% of diabetic subjects was unfortunately labile to acid hydrolysis and the involvement of glucose in its structure remains to be confirmed. However, the second fluorophore with excitation-emission maxima at 335 and 385 nm, respectively, was resistant to acid hydrolysis, and its structure could be elucidated and verified by total synthesis (3) . It revealed the presence ofa crosslink between L-lysine and L-arginine residues that could be synthesized by ribose (Fig. 1) . Because other pentoses could also serve as precursors of the crosslink, this advanced glycosylation endproduct was named pentosidine. The overall order of reactivity of pentoses in the synthesis of pentosidine with collagen followed the sequence ribose > lyxose > arabinose xylose. Hexoses and pentuloses like xylulose and ribulose were unable to produce the crosslink.
The involvement of a pentose in the crosslink was unexpected for two reasons. First, total plasma pentose concentration in the human is 100 times less than that of glucose, an observation that may have evolutionary significance since rodents have very high ribose concentrations (4) and a short lifespan that could be related to accelerated ribose-mediated crosslinking. Second, a survey of the literature revealed that, aside from essential pentosuria, abnormalities of pentose metabolism were virtually unexplored except for rare and remote studies on ribose disposal rates in diabetes (5, 6) .
The availability of pentosidine that can be quantitated in tissues at the picomole level suggested that it could be useful for the clinical assessment of impaired pentose metabolism, if indeed such abnormality exists. To investigate this hypothesis, a pilot study on (moderate), 2 (severe, requiring hemodialysis and/or renal transplant); nephrosclerosis, 0 (absent), 1 (present); systemic and coronary atherosclerosis, 0 (not visually detectable), I (mild), 2 (moderate), 3 (severe); hypertension, 0 (absent), 1 (present).
The data on nondiabetic and diabetic subjects are summarized in Table I . The diagnosis of diabetes was based on information available from the chart.
Preparation of skin collagen for HPLC assay. Insoluble collagen was prepared from skin samples as previously described (1 Assay for collagen. Collagen was quantitated by assaying for hydroxyproline by the method of Stegeman and Stalder (7). The amount of collagen was estimated assuming a content of 14% hydroxyproline by weight (8) .
Statistical analysis. Normality and variance equalities were tested according to the procedures of Shapiro and Wilk (9) and Steel and Torrie (10), respectively. Data were transformed by use of the square root transformation according to Steel and Torrie (10) . Simple and multiple regression techniques were from Neter and Wasserman (I 1) with use of methods available in the SPSS/PC+ statistical software (12) . Confidence interval for the regression line was computed using the error of prediction formula given by Armitage (13) . The Wilcoxon-Mann-Whitney two-sample test was from Steel and Torme (10).
1. Abbreviations used in this paper: ESR, end-stage renal disease; HFBA, heptafluorobutyric acid.
Results
The effect of age on pentosidine level in skin of individuals without diabetes or renal failure is shown in Fig. 3 . A curvilinear, exponential increase was noted with age that corresponded to a sixfold increase between 10 and 100 yr; however, beyond the age of 80 yr pentosidine values started to spread, some being very high while others remained low. The three highest values were found in subjects with no apparent metabolic disease who died of congestive heart failure (age 85) and sepsis (ages 84 and 89), respectively. Surprisingly, the one individual with a level below the confidence interval died from a ruptured aortic aneurysm associated with severe atherosclerosis.
The relationship between age, diabetes, renal disease, and pentosidine level in control subjects is shown in Fig. 4 . In further refinement, the effect of age was removed and subjects with renal disease were reclassified for severity (Fig. 5) . The highest levels were noted for nondiabetic and diabetic individuals with end-stage renal disease (ESR) requiring hemodialysis and/or renal transplant. Renal failure without ESR, however, did not cause elevation of pentosidine in nondiabetic or noninsulin dependent diabetic subjects (Figs. 4 
and 5).
Moderately elevated levels were found in four individuals with type I diabetes who had no overt renal complications (Fig.  4) . Two died from complications ofcystic fibrosis (ages 21 and 33), one from trauma (age 28), and one from complications of bypass surgery (age 44). This latter hypertensive individual had diabetes for 24 yr and a smoking history of 30 yr associated with complications of severe coronary and systemic atherosclerosis, but apparently no renal or retinal problems.
Pentosidine level in subjects with type II diabetes without renal failure exhibited no set pattern with regard to duration of diabetes, treatment, or complications. Four individuals had pentosidine levels on or above the confidence interval. One had diabetes for 1 yr and died from prostatic cancer (age 70), and the other three had diabetes for 5 (age 42), 8 (age 59), and 10 yr (age 83) and died from congestive heart failure associated with atherosclerotic cardiovascular disease.
Of the six individuals with type II diabetes with chronic renal insufficiency, pentosidine levels were normal in three subjects (ages 68, 75, and 85) with mild renal failure. Elevated pentosidine levels were found in two subjects with ESR requiring hemodialysis (ages 46 and 61). A striking observation was that all diabetic individuals with renal failure and levels outside the confidence interval had retinopathy implicitly mentioned in their postmortem record, while no mention of this diagnosis was made for subjects with levels found within the confidence interval for control subjects.
As noted above, severity of renal failure appeared to play a role in explaining the increase in pentosidine in nondiabetic individuals as well. Subjects with mild chronic renal insufficiency had levels within the confidence interval. In all three subjects with ESR requiring hemodialysis, elevated pentosidine levels were observed (Figs. 4 and 5) . The 29-yr-old subject with moderate elevation of pentosidine (Fig. 4) before death due to heart failure associated with severe atherosclerotic heart disease. For statistical evaluation, pentosidine levels were adjusted for age and classified into nine different groups (Fig. 5) . Due to large differences in the range of pentosidine level within groups, means were compared by a nonparametric statistic rather than by analysis ofvariance, and a multiple comparison test because variance was not homogenous among groups even with statistical transformation. Results confirmed the visual impression that mean pentosidine level for nondiabetic controls was significantly less than for the following groups: nondiabetic individuals with ESR, P < 0.002; type I diabetic subjects without renal failure, P < 0.001, and with ESR, P < 0.0001. Mean pentosidine level was not significantly elevated in subjects with type II diabetes unless ESR was present (P < 0.004).
Multivariate analysis was used to evaluate the correlation between pentosidine level, age, race, sex, presence and type of diabetes, severity of renal failure, atherosclerosis, nephrosclerosis, and hypertension. Age (P < 0.001) and renal failure (P Pentosidine levels expressed as a function of age for nondiabetic subjects without renal failure (Table I) , together with a regression line and a 95% confidence interval. An age-dependent variation was noted which was particularly large for ages > 80 yr. Therefore, in computing the regression line, data points from ages 8-80 were used, which were on the part of the plot exhibiting less variability. For statistical computation and to further stabilize the variation, all data were initially transformed using the square root transformation (10, 
Discussion
The results of pentosidine measurer gen suggests the presence of a profi tose metabolism in subjects with ES The abnormality seems to be accent to be present to a milder degree in s quantitating pentoses and the lack of an incentive for such uated by diabetes and also measurements until now. ome diabetic subjects that
The biological consequences of increased pentose-mediated crosslinking in ESR can be modeled according to those attributed to the advanced glycosylation reaction in diabetes (17) . In effect, the complications of chronic renal failure resemble those of diabetes, both being characterized by accelerated cardiovascular disease (18) , microangiopathy and basement membrane thickening (19) , impaired T cell function (20, 21) , cataracts, and peripheral neuropathy, to mention just a ,~few (22 (24) . Although abnormalities of pentose metabolism were most dramatically revealed by pentosidine in uremic subjects, more moderate but significant abnormalities were also apparent in very old age and in some diabetic individuals. The observation that all diabetic subjects with elevated pentosidine levels had retinopathy may signal a preexisting subtle impairment of pentose metabolism predictive for the risk of developing microvascular disease under hyperglycemic stress. A systematic investigation of that question is indicated.
Because pentosidine was also detected in human red blood cells and plasma proteins (3) it is likely that the abnormalities described above and others yet to be uncovered could be assessed by using a blood-based instead of a skin-biopsy assay for pentosidine. Its presence in red blood cells is expected to provide information on cumulative pentosemia in analogy to the information provided by glycohemoglobin on cumulative glycemia. These considerations suggest that pentosidine might become a prime tool for the assessment and management of disorders of pentose metabolism.
